Authorization Received from UK and EU Authorities to Activate ex-US Clinical Trial Sites Supporting the Ongoing Patient ...

Translational study shows that multiple immunological biomarkers predict the clinical activity of PDS0101 combination therapy PDS01ADC reprograms ...

Phase 3 accelerated approval trial of IFx-2.0 as adjunctive therapy with Keytruda® (pembrolizumab) as a first-line therapy ...

Record quarterly revenue of $10.1 million in Q3; a more than 6-fold increase YoY and 60% growth QoQ With a pro-forma cash balance of $840.4 million, we believe Ondas has one of the strongest balance ...

Thank you, Michael, and welcome to our third quarter 2025 earnings call. Ensuring we remain the home of the free in the land of the brave, Firefly Aerospace Inc. proudly employs many veterans like ...

Many climate scientists call our current epoch the “Anthropocene” — the first human-driven climate era. Many technologists ...

Atossa Therapeutics, Inc. (Atossa or the Company), a clinical-stage biopharmaceutical company developing proprietary innovative medicines in areas of significant unmet medical need in oncology, today ...

As AI infrastructure expands worldwide, that appetite for conductive metals is projected to rise sharply. Positioned to meet this growing need, ESGold Corp. (CSE: ESAU) (OTCQB: ESAUF) ( Profile ) is ...

ClearPoint Neuro, Inc. ( CLPT) Q3 2025 Earnings Call November 6, 2025 5:00 PM EST [Audio Gap] comments made on this call may include statements that are forward-looking within the meaning of ...

I still remember the first time I caught my nephew sneaking a third juice box at a family barbecue. He was six, all sticky ...

Total net revenue increased 20.5% to $17.6 million for third quarter of 2025 compared to the third quarter of 2024 Fortress subsidiary Checkpoint ...